Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer

OBJECTIVE: The aim of this study is to determine the outcome of trastuzumab therapy for 6 or 12 months in patients with HER2 positive operable breast cancer who followed the national health insurance system in Indonesia. METHODS: Data were extracted from medical records of Dr. M Djamil General Hospi...

Descripción completa

Detalles Bibliográficos
Autores principales: Harahap, Wirsma Arif, Ramadhan, Khambri, Daan, Haryono, Samuel, Nindrea, Ricvan Dana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494230/
https://www.ncbi.nlm.nih.gov/pubmed/28548467
http://dx.doi.org/10.22034/APJCP.2017.18.4.1151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494230/
https://www.ncbi.nlm.nih.gov/pubmed/28548467
http://dx.doi.org/10.22034/APJCP.2017.18.4.1151

Ejemplares similares